ACRS
Aclaris Therapeutics Inc

4,954
Mkt Cap
$354.29M
Volume
1.68M
52W High
$3.57
52W Low
$1.05
PE Ratio
-2.37
ACRS Fundamentals
Price
$3.38
Prev Close
$3.27
Open
$3.35
50D MA
$2.37
Beta
1.19
Avg. Volume
1.37M
EPS (Annual)
-$1.71
P/B
2.95
Rev/Employee
$292,500.00
Loading...
Loading...
News
all
press releases
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six analysts that are presently covering the firm, MarketBeat Ratings...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six analysts that are presently covering the firm, MarketBeat Ratings...
MarketBeat·8d ago
News Placeholder
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six analysts that are presently covering the firm, MarketBeat Ratings...
MarketBeat·8d ago
News Placeholder
HC Wainwright Has Strong Outlook for ACRS FY2025 Earnings
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued on Sunday...
MarketBeat·28d ago
News Placeholder
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten analysts that are currently covering the company...
MarketBeat·1mo ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of...
MarketBeat·1mo ago
News Placeholder
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.69% and +107.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates
Corcept (CORT) delivered earnings and revenue surprises of -11.11% and -5.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?
Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·2mo ago
News Placeholder
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·3mo ago

Latest ACRS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.